Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
31,889
archived clinical trials in
Blood Cancer

Study of CEP-701 (Lestaurtinib) in Patients With Acute Myeloid Leukemia (AML)
A Randomized, Open-Label Study of Oral CEP-701 Administered in Sequence With Standard Chemotherapy to Patients With Relapsed Acute Myeloid Leukemia (AML) Expressing FLT-3 Activating Mutations
Status: Enrolling
Updated:  3/16/2016
Univeristy of Maryland Medicine - Greenebaum Cancer Center
mi
from
Baltimore, MD
Study of CEP-701 (Lestaurtinib) in Patients With Acute Myeloid Leukemia (AML)
A Randomized, Open-Label Study of Oral CEP-701 Administered in Sequence With Standard Chemotherapy to Patients With Relapsed Acute Myeloid Leukemia (AML) Expressing FLT-3 Activating Mutations
Status: Enrolling
Updated: 3/16/2016
Univeristy of Maryland Medicine - Greenebaum Cancer Center
mi
from
Baltimore, MD
Click here to add this to my saved trials
Study of CEP-701 (Lestaurtinib) in Patients With Acute Myeloid Leukemia (AML)
A Randomized, Open-Label Study of Oral CEP-701 Administered in Sequence With Standard Chemotherapy to Patients With Relapsed Acute Myeloid Leukemia (AML) Expressing FLT-3 Activating Mutations
Status: Enrolling
Updated:  3/16/2016
Johns Hopkins
mi
from
Baltimore, MD
Study of CEP-701 (Lestaurtinib) in Patients With Acute Myeloid Leukemia (AML)
A Randomized, Open-Label Study of Oral CEP-701 Administered in Sequence With Standard Chemotherapy to Patients With Relapsed Acute Myeloid Leukemia (AML) Expressing FLT-3 Activating Mutations
Status: Enrolling
Updated: 3/16/2016
Johns Hopkins
mi
from
Baltimore, MD
Click here to add this to my saved trials
Study of CEP-701 (Lestaurtinib) in Patients With Acute Myeloid Leukemia (AML)
A Randomized, Open-Label Study of Oral CEP-701 Administered in Sequence With Standard Chemotherapy to Patients With Relapsed Acute Myeloid Leukemia (AML) Expressing FLT-3 Activating Mutations
Status: Enrolling
Updated:  3/16/2016
Tufts - New England Medical Center
mi
from
Boston, MA
Study of CEP-701 (Lestaurtinib) in Patients With Acute Myeloid Leukemia (AML)
A Randomized, Open-Label Study of Oral CEP-701 Administered in Sequence With Standard Chemotherapy to Patients With Relapsed Acute Myeloid Leukemia (AML) Expressing FLT-3 Activating Mutations
Status: Enrolling
Updated: 3/16/2016
Tufts - New England Medical Center
mi
from
Boston, MA
Click here to add this to my saved trials
Study of CEP-701 (Lestaurtinib) in Patients With Acute Myeloid Leukemia (AML)
A Randomized, Open-Label Study of Oral CEP-701 Administered in Sequence With Standard Chemotherapy to Patients With Relapsed Acute Myeloid Leukemia (AML) Expressing FLT-3 Activating Mutations
Status: Enrolling
Updated:  3/16/2016
Beth Israel Hospital
mi
from
Boston, MA
Study of CEP-701 (Lestaurtinib) in Patients With Acute Myeloid Leukemia (AML)
A Randomized, Open-Label Study of Oral CEP-701 Administered in Sequence With Standard Chemotherapy to Patients With Relapsed Acute Myeloid Leukemia (AML) Expressing FLT-3 Activating Mutations
Status: Enrolling
Updated: 3/16/2016
Beth Israel Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
Study of CEP-701 (Lestaurtinib) in Patients With Acute Myeloid Leukemia (AML)
A Randomized, Open-Label Study of Oral CEP-701 Administered in Sequence With Standard Chemotherapy to Patients With Relapsed Acute Myeloid Leukemia (AML) Expressing FLT-3 Activating Mutations
Status: Enrolling
Updated:  3/16/2016
University of Michigan
mi
from
Ann Arbor, MI
Study of CEP-701 (Lestaurtinib) in Patients With Acute Myeloid Leukemia (AML)
A Randomized, Open-Label Study of Oral CEP-701 Administered in Sequence With Standard Chemotherapy to Patients With Relapsed Acute Myeloid Leukemia (AML) Expressing FLT-3 Activating Mutations
Status: Enrolling
Updated: 3/16/2016
University of Michigan
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Study of CEP-701 (Lestaurtinib) in Patients With Acute Myeloid Leukemia (AML)
A Randomized, Open-Label Study of Oral CEP-701 Administered in Sequence With Standard Chemotherapy to Patients With Relapsed Acute Myeloid Leukemia (AML) Expressing FLT-3 Activating Mutations
Status: Enrolling
Updated:  3/16/2016
Karmanos Cancer Institute/Wayne State University
mi
from
Detroit, MI
Study of CEP-701 (Lestaurtinib) in Patients With Acute Myeloid Leukemia (AML)
A Randomized, Open-Label Study of Oral CEP-701 Administered in Sequence With Standard Chemotherapy to Patients With Relapsed Acute Myeloid Leukemia (AML) Expressing FLT-3 Activating Mutations
Status: Enrolling
Updated: 3/16/2016
Karmanos Cancer Institute/Wayne State University
mi
from
Detroit, MI
Click here to add this to my saved trials
Study of CEP-701 (Lestaurtinib) in Patients With Acute Myeloid Leukemia (AML)
A Randomized, Open-Label Study of Oral CEP-701 Administered in Sequence With Standard Chemotherapy to Patients With Relapsed Acute Myeloid Leukemia (AML) Expressing FLT-3 Activating Mutations
Status: Enrolling
Updated:  3/16/2016
Univ of Minnesota
mi
from
Minneapolis, MN
Study of CEP-701 (Lestaurtinib) in Patients With Acute Myeloid Leukemia (AML)
A Randomized, Open-Label Study of Oral CEP-701 Administered in Sequence With Standard Chemotherapy to Patients With Relapsed Acute Myeloid Leukemia (AML) Expressing FLT-3 Activating Mutations
Status: Enrolling
Updated: 3/16/2016
Univ of Minnesota
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Study of CEP-701 (Lestaurtinib) in Patients With Acute Myeloid Leukemia (AML)
A Randomized, Open-Label Study of Oral CEP-701 Administered in Sequence With Standard Chemotherapy to Patients With Relapsed Acute Myeloid Leukemia (AML) Expressing FLT-3 Activating Mutations
Status: Enrolling
Updated:  3/16/2016
The Mayo Clinic
mi
from
Rochester, MN
Study of CEP-701 (Lestaurtinib) in Patients With Acute Myeloid Leukemia (AML)
A Randomized, Open-Label Study of Oral CEP-701 Administered in Sequence With Standard Chemotherapy to Patients With Relapsed Acute Myeloid Leukemia (AML) Expressing FLT-3 Activating Mutations
Status: Enrolling
Updated: 3/16/2016
The Mayo Clinic
mi
from
Rochester, MN
Click here to add this to my saved trials
Study of CEP-701 (Lestaurtinib) in Patients With Acute Myeloid Leukemia (AML)
A Randomized, Open-Label Study of Oral CEP-701 Administered in Sequence With Standard Chemotherapy to Patients With Relapsed Acute Myeloid Leukemia (AML) Expressing FLT-3 Activating Mutations
Status: Enrolling
Updated:  3/16/2016
Washington University
mi
from
St. Louis, MO
Study of CEP-701 (Lestaurtinib) in Patients With Acute Myeloid Leukemia (AML)
A Randomized, Open-Label Study of Oral CEP-701 Administered in Sequence With Standard Chemotherapy to Patients With Relapsed Acute Myeloid Leukemia (AML) Expressing FLT-3 Activating Mutations
Status: Enrolling
Updated: 3/16/2016
Washington University
mi
from
St. Louis, MO
Click here to add this to my saved trials
Study of CEP-701 (Lestaurtinib) in Patients With Acute Myeloid Leukemia (AML)
A Randomized, Open-Label Study of Oral CEP-701 Administered in Sequence With Standard Chemotherapy to Patients With Relapsed Acute Myeloid Leukemia (AML) Expressing FLT-3 Activating Mutations
Status: Enrolling
Updated:  3/16/2016
University of Nebraska
mi
from
Omaha, NE
Study of CEP-701 (Lestaurtinib) in Patients With Acute Myeloid Leukemia (AML)
A Randomized, Open-Label Study of Oral CEP-701 Administered in Sequence With Standard Chemotherapy to Patients With Relapsed Acute Myeloid Leukemia (AML) Expressing FLT-3 Activating Mutations
Status: Enrolling
Updated: 3/16/2016
University of Nebraska
mi
from
Omaha, NE
Click here to add this to my saved trials
Study of CEP-701 (Lestaurtinib) in Patients With Acute Myeloid Leukemia (AML)
A Randomized, Open-Label Study of Oral CEP-701 Administered in Sequence With Standard Chemotherapy to Patients With Relapsed Acute Myeloid Leukemia (AML) Expressing FLT-3 Activating Mutations
Status: Enrolling
Updated:  3/16/2016
Roswell Park Cancer Institute
mi
from
Buffalo, NY
Study of CEP-701 (Lestaurtinib) in Patients With Acute Myeloid Leukemia (AML)
A Randomized, Open-Label Study of Oral CEP-701 Administered in Sequence With Standard Chemotherapy to Patients With Relapsed Acute Myeloid Leukemia (AML) Expressing FLT-3 Activating Mutations
Status: Enrolling
Updated: 3/16/2016
Roswell Park Cancer Institute
mi
from
Buffalo, NY
Click here to add this to my saved trials
Study of CEP-701 (Lestaurtinib) in Patients With Acute Myeloid Leukemia (AML)
A Randomized, Open-Label Study of Oral CEP-701 Administered in Sequence With Standard Chemotherapy to Patients With Relapsed Acute Myeloid Leukemia (AML) Expressing FLT-3 Activating Mutations
Status: Enrolling
Updated:  3/16/2016
New York Presbyterian
mi
from
New York, NY
Study of CEP-701 (Lestaurtinib) in Patients With Acute Myeloid Leukemia (AML)
A Randomized, Open-Label Study of Oral CEP-701 Administered in Sequence With Standard Chemotherapy to Patients With Relapsed Acute Myeloid Leukemia (AML) Expressing FLT-3 Activating Mutations
Status: Enrolling
Updated: 3/16/2016
New York Presbyterian
mi
from
New York, NY
Click here to add this to my saved trials
Study of CEP-701 (Lestaurtinib) in Patients With Acute Myeloid Leukemia (AML)
A Randomized, Open-Label Study of Oral CEP-701 Administered in Sequence With Standard Chemotherapy to Patients With Relapsed Acute Myeloid Leukemia (AML) Expressing FLT-3 Activating Mutations
Status: Enrolling
Updated:  3/16/2016
Duke Univ Med Ctr
mi
from
Durham, NC
Study of CEP-701 (Lestaurtinib) in Patients With Acute Myeloid Leukemia (AML)
A Randomized, Open-Label Study of Oral CEP-701 Administered in Sequence With Standard Chemotherapy to Patients With Relapsed Acute Myeloid Leukemia (AML) Expressing FLT-3 Activating Mutations
Status: Enrolling
Updated: 3/16/2016
Duke Univ Med Ctr
mi
from
Durham, NC
Click here to add this to my saved trials
Study of CEP-701 (Lestaurtinib) in Patients With Acute Myeloid Leukemia (AML)
A Randomized, Open-Label Study of Oral CEP-701 Administered in Sequence With Standard Chemotherapy to Patients With Relapsed Acute Myeloid Leukemia (AML) Expressing FLT-3 Activating Mutations
Status: Enrolling
Updated:  3/16/2016
Cleveland Clinic Foundation
mi
from
Cleveland, OH
Study of CEP-701 (Lestaurtinib) in Patients With Acute Myeloid Leukemia (AML)
A Randomized, Open-Label Study of Oral CEP-701 Administered in Sequence With Standard Chemotherapy to Patients With Relapsed Acute Myeloid Leukemia (AML) Expressing FLT-3 Activating Mutations
Status: Enrolling
Updated: 3/16/2016
Cleveland Clinic Foundation
mi
from
Cleveland, OH
Click here to add this to my saved trials
Study of CEP-701 (Lestaurtinib) in Patients With Acute Myeloid Leukemia (AML)
A Randomized, Open-Label Study of Oral CEP-701 Administered in Sequence With Standard Chemotherapy to Patients With Relapsed Acute Myeloid Leukemia (AML) Expressing FLT-3 Activating Mutations
Status: Enrolling
Updated:  3/16/2016
Univ of Pennsylvania
mi
from
Philadelphia, PA
Study of CEP-701 (Lestaurtinib) in Patients With Acute Myeloid Leukemia (AML)
A Randomized, Open-Label Study of Oral CEP-701 Administered in Sequence With Standard Chemotherapy to Patients With Relapsed Acute Myeloid Leukemia (AML) Expressing FLT-3 Activating Mutations
Status: Enrolling
Updated: 3/16/2016
Univ of Pennsylvania
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Study of CEP-701 (Lestaurtinib) in Patients With Acute Myeloid Leukemia (AML)
A Randomized, Open-Label Study of Oral CEP-701 Administered in Sequence With Standard Chemotherapy to Patients With Relapsed Acute Myeloid Leukemia (AML) Expressing FLT-3 Activating Mutations
Status: Enrolling
Updated:  3/16/2016
University of Pittsburgh
mi
from
Pittsburgh, PA
Study of CEP-701 (Lestaurtinib) in Patients With Acute Myeloid Leukemia (AML)
A Randomized, Open-Label Study of Oral CEP-701 Administered in Sequence With Standard Chemotherapy to Patients With Relapsed Acute Myeloid Leukemia (AML) Expressing FLT-3 Activating Mutations
Status: Enrolling
Updated: 3/16/2016
University of Pittsburgh
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Study of CEP-701 (Lestaurtinib) in Patients With Acute Myeloid Leukemia (AML)
A Randomized, Open-Label Study of Oral CEP-701 Administered in Sequence With Standard Chemotherapy to Patients With Relapsed Acute Myeloid Leukemia (AML) Expressing FLT-3 Activating Mutations
Status: Enrolling
Updated:  3/16/2016
Medical University of South Carolina
mi
from
Charleston, SC
Study of CEP-701 (Lestaurtinib) in Patients With Acute Myeloid Leukemia (AML)
A Randomized, Open-Label Study of Oral CEP-701 Administered in Sequence With Standard Chemotherapy to Patients With Relapsed Acute Myeloid Leukemia (AML) Expressing FLT-3 Activating Mutations
Status: Enrolling
Updated: 3/16/2016
Medical University of South Carolina
mi
from
Charleston, SC
Click here to add this to my saved trials
Study of CEP-701 (Lestaurtinib) in Patients With Acute Myeloid Leukemia (AML)
A Randomized, Open-Label Study of Oral CEP-701 Administered in Sequence With Standard Chemotherapy to Patients With Relapsed Acute Myeloid Leukemia (AML) Expressing FLT-3 Activating Mutations
Status: Enrolling
Updated:  3/16/2016
ACORN - The West Clinic
mi
from
Memphis, TN
Study of CEP-701 (Lestaurtinib) in Patients With Acute Myeloid Leukemia (AML)
A Randomized, Open-Label Study of Oral CEP-701 Administered in Sequence With Standard Chemotherapy to Patients With Relapsed Acute Myeloid Leukemia (AML) Expressing FLT-3 Activating Mutations
Status: Enrolling
Updated: 3/16/2016
ACORN - The West Clinic
mi
from
Memphis, TN
Click here to add this to my saved trials
Study of CEP-701 (Lestaurtinib) in Patients With Acute Myeloid Leukemia (AML)
A Randomized, Open-Label Study of Oral CEP-701 Administered in Sequence With Standard Chemotherapy to Patients With Relapsed Acute Myeloid Leukemia (AML) Expressing FLT-3 Activating Mutations
Status: Enrolling
Updated:  3/16/2016
M.D. Anderson Cancer Center
mi
from
Houston, TX
Study of CEP-701 (Lestaurtinib) in Patients With Acute Myeloid Leukemia (AML)
A Randomized, Open-Label Study of Oral CEP-701 Administered in Sequence With Standard Chemotherapy to Patients With Relapsed Acute Myeloid Leukemia (AML) Expressing FLT-3 Activating Mutations
Status: Enrolling
Updated: 3/16/2016
M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Study of CEP-701 (Lestaurtinib) in Patients With Acute Myeloid Leukemia (AML)
A Randomized, Open-Label Study of Oral CEP-701 Administered in Sequence With Standard Chemotherapy to Patients With Relapsed Acute Myeloid Leukemia (AML) Expressing FLT-3 Activating Mutations
Status: Enrolling
Updated:  3/16/2016
University of Washington Medical Center
mi
from
Seattle, WA
Study of CEP-701 (Lestaurtinib) in Patients With Acute Myeloid Leukemia (AML)
A Randomized, Open-Label Study of Oral CEP-701 Administered in Sequence With Standard Chemotherapy to Patients With Relapsed Acute Myeloid Leukemia (AML) Expressing FLT-3 Activating Mutations
Status: Enrolling
Updated: 3/16/2016
University of Washington Medical Center
mi
from
Seattle, WA
Click here to add this to my saved trials
Study of CEP-701 (Lestaurtinib) in Patients With Acute Myeloid Leukemia (AML)
A Randomized, Open-Label Study of Oral CEP-701 Administered in Sequence With Standard Chemotherapy to Patients With Relapsed Acute Myeloid Leukemia (AML) Expressing FLT-3 Activating Mutations
Status: Enrolling
Updated:  3/16/2016
mi
from
Sydney,
Study of CEP-701 (Lestaurtinib) in Patients With Acute Myeloid Leukemia (AML)
A Randomized, Open-Label Study of Oral CEP-701 Administered in Sequence With Standard Chemotherapy to Patients With Relapsed Acute Myeloid Leukemia (AML) Expressing FLT-3 Activating Mutations
Status: Enrolling
Updated: 3/16/2016
mi
from
Sydney,
Click here to add this to my saved trials
Reversible Secondary Myelofibrosis or Clonal Myeloproliferative Disorder
Reversible Secondary Myelofibrosis or Clonal Myeloproliferative Disorder
Status: Enrolling
Updated:  3/17/2016
University of Utah
mi
from
Salt Lake City, UT
Reversible Secondary Myelofibrosis or Clonal Myeloproliferative Disorder
Reversible Secondary Myelofibrosis or Clonal Myeloproliferative Disorder
Status: Enrolling
Updated: 3/17/2016
University of Utah
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
Reversible Secondary Myelofibrosis or Clonal Myeloproliferative Disorder
Reversible Secondary Myelofibrosis or Clonal Myeloproliferative Disorder
Status: Enrolling
Updated:  3/17/2016
VA Salt Lake City Health Care System
mi
from
Salt Lake City, UT
Reversible Secondary Myelofibrosis or Clonal Myeloproliferative Disorder
Reversible Secondary Myelofibrosis or Clonal Myeloproliferative Disorder
Status: Enrolling
Updated: 3/17/2016
VA Salt Lake City Health Care System
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
Low-Dose or High-Dose Vincristine and Combination Chemotherapy in Treating Young Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia
Intensive Treatment for Intermediate-Risk Relapse of Childhood B-precursor Acute Lymphoblastic Leukemia (ALL): A Randomized Trial of Vincristine Strategies
Status: Enrolling
Updated:  3/18/2016
Phoenix Children's Hospital
mi
from
Phoenix, AZ
Low-Dose or High-Dose Vincristine and Combination Chemotherapy in Treating Young Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia
Intensive Treatment for Intermediate-Risk Relapse of Childhood B-precursor Acute Lymphoblastic Leukemia (ALL): A Randomized Trial of Vincristine Strategies
Status: Enrolling
Updated: 3/18/2016
Phoenix Children's Hospital
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Low-Dose or High-Dose Vincristine and Combination Chemotherapy in Treating Young Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia
Intensive Treatment for Intermediate-Risk Relapse of Childhood B-precursor Acute Lymphoblastic Leukemia (ALL): A Randomized Trial of Vincristine Strategies
Status: Enrolling
Updated:  3/18/2016
Southern California Permanente Medical Group
mi
from
Downey, CA
Low-Dose or High-Dose Vincristine and Combination Chemotherapy in Treating Young Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia
Intensive Treatment for Intermediate-Risk Relapse of Childhood B-precursor Acute Lymphoblastic Leukemia (ALL): A Randomized Trial of Vincristine Strategies
Status: Enrolling
Updated: 3/18/2016
Southern California Permanente Medical Group
mi
from
Downey, CA
Click here to add this to my saved trials
Low-Dose or High-Dose Vincristine and Combination Chemotherapy in Treating Young Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia
Intensive Treatment for Intermediate-Risk Relapse of Childhood B-precursor Acute Lymphoblastic Leukemia (ALL): A Randomized Trial of Vincristine Strategies
Status: Enrolling
Updated:  3/18/2016
Children's Hospital Central California
mi
from
Madera, CA
Low-Dose or High-Dose Vincristine and Combination Chemotherapy in Treating Young Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia
Intensive Treatment for Intermediate-Risk Relapse of Childhood B-precursor Acute Lymphoblastic Leukemia (ALL): A Randomized Trial of Vincristine Strategies
Status: Enrolling
Updated: 3/18/2016
Children's Hospital Central California
mi
from
Madera, CA
Click here to add this to my saved trials
Low-Dose or High-Dose Vincristine and Combination Chemotherapy in Treating Young Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia
Intensive Treatment for Intermediate-Risk Relapse of Childhood B-precursor Acute Lymphoblastic Leukemia (ALL): A Randomized Trial of Vincristine Strategies
Status: Enrolling
Updated:  3/18/2016
Children's Hospital and Research Center Oakland
mi
from
Oakland, CA
Low-Dose or High-Dose Vincristine and Combination Chemotherapy in Treating Young Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia
Intensive Treatment for Intermediate-Risk Relapse of Childhood B-precursor Acute Lymphoblastic Leukemia (ALL): A Randomized Trial of Vincristine Strategies
Status: Enrolling
Updated: 3/18/2016
Children's Hospital and Research Center Oakland
mi
from
Oakland, CA
Click here to add this to my saved trials
Low-Dose or High-Dose Vincristine and Combination Chemotherapy in Treating Young Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia
Intensive Treatment for Intermediate-Risk Relapse of Childhood B-precursor Acute Lymphoblastic Leukemia (ALL): A Randomized Trial of Vincristine Strategies
Status: Enrolling
Updated:  3/18/2016
Children's Hospital of Orange County
mi
from
Orange, CA
Low-Dose or High-Dose Vincristine and Combination Chemotherapy in Treating Young Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia
Intensive Treatment for Intermediate-Risk Relapse of Childhood B-precursor Acute Lymphoblastic Leukemia (ALL): A Randomized Trial of Vincristine Strategies
Status: Enrolling
Updated: 3/18/2016
Children's Hospital of Orange County
mi
from
Orange, CA
Click here to add this to my saved trials
Low-Dose or High-Dose Vincristine and Combination Chemotherapy in Treating Young Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia
Intensive Treatment for Intermediate-Risk Relapse of Childhood B-precursor Acute Lymphoblastic Leukemia (ALL): A Randomized Trial of Vincristine Strategies
Status: Enrolling
Updated:  3/18/2016
Lucile Packard Children's Hospital Stanford University
mi
from
Palo Alto, CA
Low-Dose or High-Dose Vincristine and Combination Chemotherapy in Treating Young Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia
Intensive Treatment for Intermediate-Risk Relapse of Childhood B-precursor Acute Lymphoblastic Leukemia (ALL): A Randomized Trial of Vincristine Strategies
Status: Enrolling
Updated: 3/18/2016
Lucile Packard Children's Hospital Stanford University
mi
from
Palo Alto, CA
Click here to add this to my saved trials
Low-Dose or High-Dose Vincristine and Combination Chemotherapy in Treating Young Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia
Intensive Treatment for Intermediate-Risk Relapse of Childhood B-precursor Acute Lymphoblastic Leukemia (ALL): A Randomized Trial of Vincristine Strategies
Status: Enrolling
Updated:  3/18/2016
Rady Children's Hospital - San Diego
mi
from
San Diego, CA
Low-Dose or High-Dose Vincristine and Combination Chemotherapy in Treating Young Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia
Intensive Treatment for Intermediate-Risk Relapse of Childhood B-precursor Acute Lymphoblastic Leukemia (ALL): A Randomized Trial of Vincristine Strategies
Status: Enrolling
Updated: 3/18/2016
Rady Children's Hospital - San Diego
mi
from
San Diego, CA
Click here to add this to my saved trials
Low-Dose or High-Dose Vincristine and Combination Chemotherapy in Treating Young Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia
Intensive Treatment for Intermediate-Risk Relapse of Childhood B-precursor Acute Lymphoblastic Leukemia (ALL): A Randomized Trial of Vincristine Strategies
Status: Enrolling
Updated:  3/18/2016
Connecticut Children's Medical Center
mi
from
Hartford, CT
Low-Dose or High-Dose Vincristine and Combination Chemotherapy in Treating Young Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia
Intensive Treatment for Intermediate-Risk Relapse of Childhood B-precursor Acute Lymphoblastic Leukemia (ALL): A Randomized Trial of Vincristine Strategies
Status: Enrolling
Updated: 3/18/2016
Connecticut Children's Medical Center
mi
from
Hartford, CT
Click here to add this to my saved trials
Low-Dose or High-Dose Vincristine and Combination Chemotherapy in Treating Young Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia
Intensive Treatment for Intermediate-Risk Relapse of Childhood B-precursor Acute Lymphoblastic Leukemia (ALL): A Randomized Trial of Vincristine Strategies
Status: Enrolling
Updated:  3/18/2016
Alfred I. duPont Hospital for Children
mi
from
Wilmington, DE
Low-Dose or High-Dose Vincristine and Combination Chemotherapy in Treating Young Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia
Intensive Treatment for Intermediate-Risk Relapse of Childhood B-precursor Acute Lymphoblastic Leukemia (ALL): A Randomized Trial of Vincristine Strategies
Status: Enrolling
Updated: 3/18/2016
Alfred I. duPont Hospital for Children
mi
from
Wilmington, DE
Click here to add this to my saved trials
Low-Dose or High-Dose Vincristine and Combination Chemotherapy in Treating Young Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia
Intensive Treatment for Intermediate-Risk Relapse of Childhood B-precursor Acute Lymphoblastic Leukemia (ALL): A Randomized Trial of Vincristine Strategies
Status: Enrolling
Updated:  3/18/2016
Childrens National Medical Center
mi
from
Washington,
Low-Dose or High-Dose Vincristine and Combination Chemotherapy in Treating Young Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia
Intensive Treatment for Intermediate-Risk Relapse of Childhood B-precursor Acute Lymphoblastic Leukemia (ALL): A Randomized Trial of Vincristine Strategies
Status: Enrolling
Updated: 3/18/2016
Childrens National Medical Center
mi
from
Washington,
Click here to add this to my saved trials
Low-Dose or High-Dose Vincristine and Combination Chemotherapy in Treating Young Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia
Intensive Treatment for Intermediate-Risk Relapse of Childhood B-precursor Acute Lymphoblastic Leukemia (ALL): A Randomized Trial of Vincristine Strategies
Status: Enrolling
Updated:  3/18/2016
Miami Children's Hospital
mi
from
Miami, FL
Low-Dose or High-Dose Vincristine and Combination Chemotherapy in Treating Young Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia
Intensive Treatment for Intermediate-Risk Relapse of Childhood B-precursor Acute Lymphoblastic Leukemia (ALL): A Randomized Trial of Vincristine Strategies
Status: Enrolling
Updated: 3/18/2016
Miami Children's Hospital
mi
from
Miami, FL
Click here to add this to my saved trials
Low-Dose or High-Dose Vincristine and Combination Chemotherapy in Treating Young Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia
Intensive Treatment for Intermediate-Risk Relapse of Childhood B-precursor Acute Lymphoblastic Leukemia (ALL): A Randomized Trial of Vincristine Strategies
Status: Enrolling
Updated:  3/18/2016
Nemours Children's Clinic - Orlando
mi
from
Orlando, FL
Low-Dose or High-Dose Vincristine and Combination Chemotherapy in Treating Young Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia
Intensive Treatment for Intermediate-Risk Relapse of Childhood B-precursor Acute Lymphoblastic Leukemia (ALL): A Randomized Trial of Vincristine Strategies
Status: Enrolling
Updated: 3/18/2016
Nemours Children's Clinic - Orlando
mi
from
Orlando, FL
Click here to add this to my saved trials
Low-Dose or High-Dose Vincristine and Combination Chemotherapy in Treating Young Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia
Intensive Treatment for Intermediate-Risk Relapse of Childhood B-precursor Acute Lymphoblastic Leukemia (ALL): A Randomized Trial of Vincristine Strategies
Status: Enrolling
Updated:  3/18/2016
Nemours Children's Clinic - Pensacola
mi
from
Pensacola, FL
Low-Dose or High-Dose Vincristine and Combination Chemotherapy in Treating Young Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia
Intensive Treatment for Intermediate-Risk Relapse of Childhood B-precursor Acute Lymphoblastic Leukemia (ALL): A Randomized Trial of Vincristine Strategies
Status: Enrolling
Updated: 3/18/2016
Nemours Children's Clinic - Pensacola
mi
from
Pensacola, FL
Click here to add this to my saved trials
Low-Dose or High-Dose Vincristine and Combination Chemotherapy in Treating Young Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia
Intensive Treatment for Intermediate-Risk Relapse of Childhood B-precursor Acute Lymphoblastic Leukemia (ALL): A Randomized Trial of Vincristine Strategies
Status: Enrolling
Updated:  3/18/2016
Saint Luke's Mountain States Tumor Institute
mi
from
Boise, ID
Low-Dose or High-Dose Vincristine and Combination Chemotherapy in Treating Young Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia
Intensive Treatment for Intermediate-Risk Relapse of Childhood B-precursor Acute Lymphoblastic Leukemia (ALL): A Randomized Trial of Vincristine Strategies
Status: Enrolling
Updated: 3/18/2016
Saint Luke's Mountain States Tumor Institute
mi
from
Boise, ID
Click here to add this to my saved trials
Low-Dose or High-Dose Vincristine and Combination Chemotherapy in Treating Young Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia
Intensive Treatment for Intermediate-Risk Relapse of Childhood B-precursor Acute Lymphoblastic Leukemia (ALL): A Randomized Trial of Vincristine Strategies
Status: Enrolling
Updated:  3/18/2016
Kosair Children's Hospital
mi
from
Louisville, KY
Low-Dose or High-Dose Vincristine and Combination Chemotherapy in Treating Young Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia
Intensive Treatment for Intermediate-Risk Relapse of Childhood B-precursor Acute Lymphoblastic Leukemia (ALL): A Randomized Trial of Vincristine Strategies
Status: Enrolling
Updated: 3/18/2016
Kosair Children's Hospital
mi
from
Louisville, KY
Click here to add this to my saved trials
Low-Dose or High-Dose Vincristine and Combination Chemotherapy in Treating Young Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia
Intensive Treatment for Intermediate-Risk Relapse of Childhood B-precursor Acute Lymphoblastic Leukemia (ALL): A Randomized Trial of Vincristine Strategies
Status: Enrolling
Updated:  3/18/2016
University of Maryland Greenebaum Cancer Center
mi
from
Baltimore, MD
Low-Dose or High-Dose Vincristine and Combination Chemotherapy in Treating Young Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia
Intensive Treatment for Intermediate-Risk Relapse of Childhood B-precursor Acute Lymphoblastic Leukemia (ALL): A Randomized Trial of Vincristine Strategies
Status: Enrolling
Updated: 3/18/2016
University of Maryland Greenebaum Cancer Center
mi
from
Baltimore, MD
Click here to add this to my saved trials
Low-Dose or High-Dose Vincristine and Combination Chemotherapy in Treating Young Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia
Intensive Treatment for Intermediate-Risk Relapse of Childhood B-precursor Acute Lymphoblastic Leukemia (ALL): A Randomized Trial of Vincristine Strategies
Status: Enrolling
Updated:  3/18/2016
Walter Reed National Military Medical Center
mi
from
Bethesda, MD
Low-Dose or High-Dose Vincristine and Combination Chemotherapy in Treating Young Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia
Intensive Treatment for Intermediate-Risk Relapse of Childhood B-precursor Acute Lymphoblastic Leukemia (ALL): A Randomized Trial of Vincristine Strategies
Status: Enrolling
Updated: 3/18/2016
Walter Reed National Military Medical Center
mi
from
Bethesda, MD
Click here to add this to my saved trials
Low-Dose or High-Dose Vincristine and Combination Chemotherapy in Treating Young Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia
Intensive Treatment for Intermediate-Risk Relapse of Childhood B-precursor Acute Lymphoblastic Leukemia (ALL): A Randomized Trial of Vincristine Strategies
Status: Enrolling
Updated:  3/18/2016
Hurley Medical Center
mi
from
Flint, MI
Low-Dose or High-Dose Vincristine and Combination Chemotherapy in Treating Young Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia
Intensive Treatment for Intermediate-Risk Relapse of Childhood B-precursor Acute Lymphoblastic Leukemia (ALL): A Randomized Trial of Vincristine Strategies
Status: Enrolling
Updated: 3/18/2016
Hurley Medical Center
mi
from
Flint, MI
Click here to add this to my saved trials
Low-Dose or High-Dose Vincristine and Combination Chemotherapy in Treating Young Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia
Intensive Treatment for Intermediate-Risk Relapse of Childhood B-precursor Acute Lymphoblastic Leukemia (ALL): A Randomized Trial of Vincristine Strategies
Status: Enrolling
Updated:  3/18/2016
Helen DeVos Children's Hospital at Spectrum Health
mi
from
Grand Rapids, MI
Low-Dose or High-Dose Vincristine and Combination Chemotherapy in Treating Young Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia
Intensive Treatment for Intermediate-Risk Relapse of Childhood B-precursor Acute Lymphoblastic Leukemia (ALL): A Randomized Trial of Vincristine Strategies
Status: Enrolling
Updated: 3/18/2016
Helen DeVos Children's Hospital at Spectrum Health
mi
from
Grand Rapids, MI
Click here to add this to my saved trials
Low-Dose or High-Dose Vincristine and Combination Chemotherapy in Treating Young Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia
Intensive Treatment for Intermediate-Risk Relapse of Childhood B-precursor Acute Lymphoblastic Leukemia (ALL): A Randomized Trial of Vincristine Strategies
Status: Enrolling
Updated:  3/18/2016
Bronson Methodist Hospital
mi
from
Kalamazoo, MI
Low-Dose or High-Dose Vincristine and Combination Chemotherapy in Treating Young Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia
Intensive Treatment for Intermediate-Risk Relapse of Childhood B-precursor Acute Lymphoblastic Leukemia (ALL): A Randomized Trial of Vincristine Strategies
Status: Enrolling
Updated: 3/18/2016
Bronson Methodist Hospital
mi
from
Kalamazoo, MI
Click here to add this to my saved trials
Low-Dose or High-Dose Vincristine and Combination Chemotherapy in Treating Young Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia
Intensive Treatment for Intermediate-Risk Relapse of Childhood B-precursor Acute Lymphoblastic Leukemia (ALL): A Randomized Trial of Vincristine Strategies
Status: Enrolling
Updated:  3/18/2016
Children's Hospitals and Clinics of Minnesota - Minneapolis
mi
from
Minneapolis, MN
Low-Dose or High-Dose Vincristine and Combination Chemotherapy in Treating Young Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia
Intensive Treatment for Intermediate-Risk Relapse of Childhood B-precursor Acute Lymphoblastic Leukemia (ALL): A Randomized Trial of Vincristine Strategies
Status: Enrolling
Updated: 3/18/2016
Children's Hospitals and Clinics of Minnesota - Minneapolis
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Low-Dose or High-Dose Vincristine and Combination Chemotherapy in Treating Young Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia
Intensive Treatment for Intermediate-Risk Relapse of Childhood B-precursor Acute Lymphoblastic Leukemia (ALL): A Randomized Trial of Vincristine Strategies
Status: Enrolling
Updated:  3/18/2016
Children's Mercy Hospital
mi
from
Kansas City, MO
Low-Dose or High-Dose Vincristine and Combination Chemotherapy in Treating Young Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia
Intensive Treatment for Intermediate-Risk Relapse of Childhood B-precursor Acute Lymphoblastic Leukemia (ALL): A Randomized Trial of Vincristine Strategies
Status: Enrolling
Updated: 3/18/2016
Children's Mercy Hospital
mi
from
Kansas City, MO
Click here to add this to my saved trials
Low-Dose or High-Dose Vincristine and Combination Chemotherapy in Treating Young Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia
Intensive Treatment for Intermediate-Risk Relapse of Childhood B-precursor Acute Lymphoblastic Leukemia (ALL): A Randomized Trial of Vincristine Strategies
Status: Enrolling
Updated:  3/18/2016
Nevada Cancer Research Foundation CCOP
mi
from
Las Vegas, NV
Low-Dose or High-Dose Vincristine and Combination Chemotherapy in Treating Young Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia
Intensive Treatment for Intermediate-Risk Relapse of Childhood B-precursor Acute Lymphoblastic Leukemia (ALL): A Randomized Trial of Vincristine Strategies
Status: Enrolling
Updated: 3/18/2016
Nevada Cancer Research Foundation CCOP
mi
from
Las Vegas, NV
Click here to add this to my saved trials
Low-Dose or High-Dose Vincristine and Combination Chemotherapy in Treating Young Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia
Intensive Treatment for Intermediate-Risk Relapse of Childhood B-precursor Acute Lymphoblastic Leukemia (ALL): A Randomized Trial of Vincristine Strategies
Status: Enrolling
Updated:  3/18/2016
Saint Peter's University Hospital
mi
from
New Brunswick, NJ
Low-Dose or High-Dose Vincristine and Combination Chemotherapy in Treating Young Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia
Intensive Treatment for Intermediate-Risk Relapse of Childhood B-precursor Acute Lymphoblastic Leukemia (ALL): A Randomized Trial of Vincristine Strategies
Status: Enrolling
Updated: 3/18/2016
Saint Peter's University Hospital
mi
from
New Brunswick, NJ
Click here to add this to my saved trials
Low-Dose or High-Dose Vincristine and Combination Chemotherapy in Treating Young Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia
Intensive Treatment for Intermediate-Risk Relapse of Childhood B-precursor Acute Lymphoblastic Leukemia (ALL): A Randomized Trial of Vincristine Strategies
Status: Enrolling
Updated:  3/18/2016
Newark Beth Israel Medical Center
mi
from
Newark, NJ
Low-Dose or High-Dose Vincristine and Combination Chemotherapy in Treating Young Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia
Intensive Treatment for Intermediate-Risk Relapse of Childhood B-precursor Acute Lymphoblastic Leukemia (ALL): A Randomized Trial of Vincristine Strategies
Status: Enrolling
Updated: 3/18/2016
Newark Beth Israel Medical Center
mi
from
Newark, NJ
Click here to add this to my saved trials
Low-Dose or High-Dose Vincristine and Combination Chemotherapy in Treating Young Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia
Intensive Treatment for Intermediate-Risk Relapse of Childhood B-precursor Acute Lymphoblastic Leukemia (ALL): A Randomized Trial of Vincristine Strategies
Status: Enrolling
Updated:  3/18/2016
University of New Mexico Cancer Center
mi
from
Albuquerque, NM
Low-Dose or High-Dose Vincristine and Combination Chemotherapy in Treating Young Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia
Intensive Treatment for Intermediate-Risk Relapse of Childhood B-precursor Acute Lymphoblastic Leukemia (ALL): A Randomized Trial of Vincristine Strategies
Status: Enrolling
Updated: 3/18/2016
University of New Mexico Cancer Center
mi
from
Albuquerque, NM
Click here to add this to my saved trials
Low-Dose or High-Dose Vincristine and Combination Chemotherapy in Treating Young Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia
Intensive Treatment for Intermediate-Risk Relapse of Childhood B-precursor Acute Lymphoblastic Leukemia (ALL): A Randomized Trial of Vincristine Strategies
Status: Enrolling
Updated:  3/18/2016
Roswell Park Cancer Institute
mi
from
Buffalo, NY
Low-Dose or High-Dose Vincristine and Combination Chemotherapy in Treating Young Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia
Intensive Treatment for Intermediate-Risk Relapse of Childhood B-precursor Acute Lymphoblastic Leukemia (ALL): A Randomized Trial of Vincristine Strategies
Status: Enrolling
Updated: 3/18/2016
Roswell Park Cancer Institute
mi
from
Buffalo, NY
Click here to add this to my saved trials